Published in TB and Outbreaks Week, June 18th, 2002
In the reported study, a tuberculosis subunit vaccine was combined with Bio-Vant in a proprietary formulation developed by scientists at BioSante's research center in Smyrna, Georgia, and immune response was tested in a mouse model. The studies were designed to test the effects of Bio-Vant on the immunogenicity elicited...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.